The ALK/MET inhibitor crizotinib, as a potential therapeutic agent for chordomas, led to a reduction of proliferation markers and the modulation of key DNA repair and cell cycle regulatory genes, with CDC20 and FOXO4 playing a pivotal role. The gene discussed is MET; the disease is chordoma.